Most relevant here, up‐regulation of the SGOC pathway correlated with MYCN amplification in neuroblastoma, and MYCN sensitized neuroblastoma cells to pharmacological inhibition of one of its components, phosphoglycerate dehydrogenase [250]. This evidence concerns the gene MYCN and neuroblastoma.